Chong-yang Sun , Zhi-yi Xiong , Cheng-yi Sun , Pei-hong Ma , Xiao-yu Liu , Chi-yun Sun , Ze-yin Xin , Bao-yan Liu , Cun-zhi Liu , Shi-yan Yan
{"title":"假针灸对原发性痛经患者的安慰剂反应:一项荟萃分析。","authors":"Chong-yang Sun , Zhi-yi Xiong , Cheng-yi Sun , Pei-hong Ma , Xiao-yu Liu , Chi-yun Sun , Ze-yin Xin , Bao-yan Liu , Cun-zhi Liu , Shi-yan Yan","doi":"10.1016/j.joim.2023.08.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The placebo response<span><span> of sham acupuncture </span>in patients<span> with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.</span></span></p></div><div><h3>Objective</h3><p>This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.</p></div><div><h3>Search strategy</h3><p>PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.</p></div><div><h3>Data extraction and analysis</h3><p>Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.</p></div><div><h3>Results</h3><p>Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.</p></div><div><h3>Conclusion</h3><p>Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.</p><p><em>PROSPERO registration number:</em> CRD42022304215.<br></p><p>Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. <em>J Integr Med</em>. 2023; 21(5): 455–463.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 455-463"},"PeriodicalIF":4.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis\",\"authors\":\"Chong-yang Sun , Zhi-yi Xiong , Cheng-yi Sun , Pei-hong Ma , Xiao-yu Liu , Chi-yun Sun , Ze-yin Xin , Bao-yan Liu , Cun-zhi Liu , Shi-yan Yan\",\"doi\":\"10.1016/j.joim.2023.08.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The placebo response<span><span> of sham acupuncture </span>in patients<span> with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.</span></span></p></div><div><h3>Objective</h3><p>This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.</p></div><div><h3>Search strategy</h3><p>PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.</p></div><div><h3>Data extraction and analysis</h3><p>Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.</p></div><div><h3>Results</h3><p>Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.</p></div><div><h3>Conclusion</h3><p>Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.</p><p><em>PROSPERO registration number:</em> CRD42022304215.<br></p><p>Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. <em>J Integr Med</em>. 2023; 21(5): 455–463.</p></div>\",\"PeriodicalId\":48599,\"journal\":{\"name\":\"Journal of Integrative Medicine-Jim\",\"volume\":\"21 5\",\"pages\":\"Pages 455-463\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Integrative Medicine-Jim\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2095496423000675\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Medicine-Jim","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2095496423000675","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
背景:假针灸对原发性痛经患者的安慰剂反应是与镇痛相关的一个重要因素。然而,安慰剂反应的程度尚不清楚。目的:本荟萃分析评估了假针灸对原发性痛经患者的疗效及其影响因素。搜索策略:从成立到2022年8月20日,检索PubMed、Embase、Web of Science和Cochrane CENTRAL数据库。纳入标准:随机对照试验(RCT)使用假针灸作为育龄女性原发性痛经患者的对照。数据提取和分析:疼痛强度、回顾性症状量表和健康相关的生活质量是这些试验中使用的结果指标。安慰剂反应被定义为从基线到终点的感兴趣结果的变化。我们使用标准化平均差(SMD)来估计安慰剂反应的影响大小。结果:纳入13项随机对照试验。合并安慰剂对疼痛强度的反应大小最大(SMD=-0.99;95%置信区间[CI],-1.31至-0.68),其次是回顾性症状量表(总频率评分:SMD=-0.20;95%CI,-0.80至-0.39)。平均严重程度评分:SMD=-0.35;95%CI,-0.90至-0.20)和SF-36的物理成分(SMD=0.27;95%CI,-0.17至0.72)。使用钝头针的研究、单中心试验、偏倚风险低的研究、患者病程较长的研究、临床医生的研究结论:原发性痛经患者存在较强的安慰剂反应和一些相关因素。PROSPERO注册号:CRD42022304215。请引用这篇文章:孙,熊,孙,马,刘XY,孙,辛,刘BY,刘CZ,颜SY。假针灸对原发性痛经患者的安慰剂反应:荟萃分析。国际医学杂志,2023;21(5):455-463。
Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis
Background
The placebo response of sham acupuncture in patients with primary dysmenorrhea is a substantial factor associated with analgesia. However, the magnitude of the placebo response is unclear.
Objective
This meta-analysis assessed the effects of sham acupuncture in patients with primary dysmenorrhea and the factors contributing to these effects.
Search strategy
PubMed, Embase, Web of Science, and Cochrane CENTRAL databases were searched from inception up to August 20, 2022.
Inclusion criteria
Randomized controlled trials (RCTs) using sham acupuncture as a control for female patients of reproductive age with primary dysmenorrhea were included.
Data extraction and analysis
Pain intensity, retrospective symptom scale, and health-related quality of life were outcome measures used in these trials. Placebo response was defined as the change in the outcome of interest from baseline to endpoint. We used standardized mean difference (SMD) to estimate the effect size of the placebo response.
Results
Thirteen RCTs were included. The pooled placebo response size for pain intensity was the largest (SMD = −0.99; 95% confidence interval [CI], −1.31 to −0.68), followed by the retrospective symptom scale (Total frequency rating score: SMD = −0.20; 95% CI, −0.80 to −0.39. Average severity score: SMD = −0.35; 95% CI, −0.90 to −0.20) and physical component of SF-36 (SMD = 0.27; 95% CI, −0.17 to 0.72). Studies using blunt-tip needles, single-center trials, studies with a low risk of bias, studies in which patients had a longer disease course, studies in which clinicians had < 5 years of experience, and trials conducted outside Asia were more likely to have a lower placebo response.
Conclusion
Strong placebo response and some relative factors were found in patients with primary dysmenorrhea.
PROSPERO registration number: CRD42022304215.
Please cite this article as: Sun CY, Xiong ZY, Sun CY, Ma PH, Liu XY, Sun CY, Xin ZY, Liu BY, Liu CZ, Yan SY. Placebo response of sham acupuncture in patients with primary dysmenorrhea: A meta-analysis. J Integr Med. 2023; 21(5): 455–463.
期刊介绍:
The predecessor of JIM is the Journal of Chinese Integrative Medicine (Zhong Xi Yi Jie He Xue Bao). With this new, English-language publication, we are committed to make JIM an international platform for publishing high-quality papers on complementary and alternative medicine (CAM) and an open forum in which the different professions and international scholarly communities can exchange views, share research and their clinical experience, discuss CAM education, and confer about issues and problems in our various disciplines and in CAM as a whole in order to promote integrative medicine.
JIM is indexed/abstracted in: MEDLINE/PubMed, ScienceDirect, Emerging Sources Citation Index (ESCI), Scopus, Embase, Chemical Abstracts (CA), CAB Abstracts, EBSCO, WPRIM, JST China, Chinese Science Citation Database (CSCD), and China National Knowledge Infrastructure (CNKI).
JIM Editorial Office uses ThomsonReuters ScholarOne Manuscripts as submitting and review system (submission link: http://mc03.manuscriptcentral.com/jcim-en).
JIM is published bimonthly. Manuscripts submitted to JIM should be written in English. Article types include but are not limited to randomized controlled and pragmatic trials, translational and patient-centered effectiveness outcome studies, case series and reports, clinical trial protocols, preclinical and basic science studies, systematic reviews and meta-analyses, papers on methodology and CAM history or education, conference proceedings, editorials, commentaries, short communications, book reviews, and letters to the editor.
Our purpose is to publish a prestigious international journal for studies in integrative medicine. To achieve this aim, we seek to publish high-quality papers on any aspects of integrative medicine, such as acupuncture and traditional Chinese medicine, Ayurveda medicine, herbal medicine, homeopathy, nutrition, chiropractic, mind-body medicine, taichi, qigong, meditation, and any other modalities of CAM; our commitment to international scope ensures that research and progress from all regions of the world are widely covered. These ensure that articles published in JIM have the maximum exposure to the international scholarly community.
JIM can help its authors let their papers reach the widest possible range of readers, and let all those who share an interest in their research field be concerned with their study.